Participants in a PET study received the tracer, then gave it time to reach the brain. Then they laid in a scanner that took ...

Over time, the neighborhood falls into disrepair. A critical protein that MSNs need to stay alive, called DARPP-32, starts to ...

June was filled with exciting research! Ranging from clinical trial updates to irritability, we’ve rounded up the most exciting Huntington’s disease research from this month.

Spark and Roche issued a joint community letter to share that the first patient has been dosed in a new HD gene therapy trial.

Minocycline: the end of the road? DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.

TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation ...

The HDBuzz team recently convened in Palm Springs, California, along with hundreds of other scientists from all over the globe, for the 19th Annual HD Therapeutics Conference, hosted by the HD ...

Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this ...

The HDBuzz editorial team had a virtual sit-down with HDBuzz founder, editor emeritus, Huntington’s disease (HD) researcher, and neurologist Professor Ed Wild. We laughed, we cried… actually we just ...

After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the ...

A highly-anticipated scientific paper has landed! This new work challenges current theories in Huntington’s disease research, uncovering how runaway CAG repeats erode cell identity in certain types of ...